Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 4Neutropenia 3Febrile Neutropenia 3Small Cell Lung Carcinoma 1Patients With Nonmyeloid Malignancies Receiving Antineoplastic Therapy Based on Chemotherapy Regimens at Moderate to High Febrile Neutropenia (FN) Risk 1Malignant Solid Tumors 1Lymphoma, Non-Hodgkin 1Lymphoma 1Chemotherapy-induced Neutropenia 1Carcinoma, Non-Small-Cell Lung 1Breast Cancer Female 1Advanced Pancreatic Cancer 1

Interventions

tislelizumab 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1olaparib 1Topotecan 1Sirolimus 1SAR125844 1Injections 1Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Malignant Solid Tumors × pegylated granulocyte colony-stimulating factor × Clear all
NCT02805166 2016-06-17

PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Phase 4 Completed
420 enrolled
Other solid neoplasm

Malignant Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡